Physician profile
Amanda Graham
NPI 1447500137
$1,812.85
in general payments reported to CMS, 2019-2025
27 companies · $596 in 2025
The $596 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $457 · 2022: $256 · 2023: $275 · 2024: $229 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $987 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $986.78 |
| Education | $113.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $250.09 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.40 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $168.81 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $151.04 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Beta Bionics, INC. | $123.28 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Abbott Laboratories | $121.14 | 2022 | |
| Tandem Diabetes Care, INC. | $88.44 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Pfizer INC. | $76.25 | 2021-2025 | |
| Medtronic, INC. | $65.59 | 2021-2023 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $57.89 | 2023-2025 | Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $55.11 | 2023-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $54.31 | 2021-2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $51.97 | 2021-2025 | Shingrix, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $42.56 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Astellas Pharma US INC | $40.96 | 2021-2025 | Veozah |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $38.45 | 2021 | |
| Dexcom, INC. | $33.29 | 2021-2024 | Dexcom G6 Transmitter |
| Organon LLC | $33.04 | 2023-2025 | Nexplanon, Nuvaring |
| Sanofi-Aventis U.S. LLC | $30.43 | 2021-2025 | |
| Exact Sciences Corporation | $27.50 | 2023 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.35 | 2024 | Caplyta |
| Regeneron Healthcare Solutions, INC. | $19.38 | 2023 | Evkeeza |
| Biohaven Pharmaceutical Holding Company LTD. | $18.64 | 2022 | |
| Lundbeck LLC | $16.82 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.48 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.05 | 2024 | Spravato |
| Phadia US INC. | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.